Hundreds of millions of people worldwide live with a high risk of developing Alzheimer’s Disease (AD). They display no cognitive symptoms but harbor insidious genetic markers of AD-related brain changes.
Simon Nicholls was one of these people. After testing positive for two copies of the ApoE4 gene and concerning blood-based biomarkers for AD, Simon wanted to take control of his health. With two children at home and lots of life left to live, he came to us
Read More
neurodegenerative diseases
NeuroSense Therapeutics and NeuraLight Collaborate to Detect ALS Oculometric Biomarkers
What You Should Know:
- NeuroSense Therapeutics Ltd., a company developing treatments for severe neurodegenerative diseases, and NeuraLight, a company developing objective and sensitive biomarkers for neurological disorders, today announced a collaboration to advance the science of digital biomarkers in the detection and monitoring of neurological diseases including amyotrophic lateral sclerosis (ALS).
- This agreement marks NeuraLight’s first clinical trial and comes on the heels of
Read More
When It Comes to Digital Health, Experience Is Everything
Thanks to COVID-19 and numerous other factors, the adoption of digital health technologies used by patients in the home has skyrocketed. Accenture reported in 2021, for example, that remote patient monitoring technology adoption tripled among patients. Whether it is streaming video telehealth appointments with a provider, a remote patient monitoring platform, or a prescribed digital therapeutic to manage a chronic condition, the emphasis must be on the patient and caregiver
Read More
Aetion and Cognito Team Up for Predictive Modeling in Alzheimer’s
What You Should Know:
- Aetion, real-world evidence (RWE) tech and analytics provider, and Cognito Therapeutics, a pioneer in neuromodulation therapeutics for neurodegenerative diseases like Alzheimer’s, are partnering to develop an AI-driven predictive model to help payers and providers identify patients with rapidly progressing mild cognitive impairment (MCI) and Alzheimer’s who may benefit from earlier treatment.
Impact of MCI & Alzheimer’s Disease
There are approximately 13.5
Read More
C. Light Launches AI-Driven Retinal Eye-Tracking; Predicts Neurological Health in 10 Seconds
- C. Light Technologies launches the world’s first AI-driven retinal eye-tracking technology to assess neurological health in the blink of an eye.
- The neurotech & AI company has the most sensitive tracker for eye motion on the cellular scale available today to predict neurological diseases in seconds.
C. Light Technologies, a Berkeley,
CA-based neurotech and AI company
participating in UC Berkeley’s premier accelerator SkyDeck, is introducing the
world’s first retinal
Read More
Philips Debuts AI-Driven Clinical Solution for Aiding Cognitive Assessment in the U.S.
- Philips IntelliSpace Cognition provides U.S. healthcare professionals with a powerful aid for assessing cognitive impairments due to neurological conditions.
- Philips has invested in collecting insights from both neurologists and neuropsychologists in order to design IntelliSpace Cognition in an iterative manner and ensure it fits into the majority of existing workflows.
- IntelliSpace Cognition will initially be commercially available only in the U.S.
Philips, a global leader in
Read More
Octave Bioscience Grabs $14M for Care Management Platform Focused on Neurodegenerative Diseases
Octave Bioscience lands $14M to bring expertise in chronic neurodegenerative markets and molecular Insights for improved care.Octave Bioscience, a Menlo Park, CA-based developer of a fully integrated care management platform delivering powerful insights for patients with neurodegenerative diseases, today announced it has raised $14 million in Series A funding. The round was led by BCBS Venture Partners with participation from Echo Health Ventures (a strategic collaboration of Cambia Health
Read More
Novartis to Acquire Gene Therapy Provider AveXis for $8.7B in Cash
Novartis announced today that is has entered into an agreement to acquire AveXis, Inc., a clinical stage gene therapy company for $8.7 billion in cash. AveXis lead product candidate, AVXS-101, has potential to be first-ever one-time gene replacement therapy for spinal muscular atrophy (SMA), a disease which results in early death or lifelong disability with considerable healthcare costs. It is estimated that one out of every 6,000-10,000 children born is affected by some form of SMA.The US Food
Read More
Northwell Health, GE Ventures Form $200M Alliance to Develop, Commercialize Solutions in Bioelectronic Medicine
Today, GE Ventures announced a strategic partnership with Northwell Health’s Feinstein Institute for Medical Research providing up to $200 million in joint funding over seven years to support the opening of a new Center for Bioelectronic Medicine (CBEM), and advance diagnostic and therapeutic solutions for Alzheimer’s, cancer, diabetes, hypertension and more. The new alliance will greatly build upon groundbreaking work that started between the Feinstein Institute and a team of GE scientists
Read More
